Table 3.
Outcomes in patients with a pregnancy (N=115).
| Outcomes | No. (%) |
|---|---|
| Pregnancy (conception) interval | |
| <1 Y after surgery | 11 (9.6) |
| 1–2 Y after surgery | 11 (9.6) |
| 2–3 Y after surgery | 24 (20.9) |
| 3–4 Y after surgery | 29 (25.2) |
| 4–5 Y after surgery | 19 (16.5) |
| 5–6 Y after surgery | 9 (7.8) |
| 6–7 Y after surgery | 6 (5.2) |
| 7–8 Y after surgery | 5 (4.3) |
| 8–9 Y after surgery | 1 (0.9) |
| No. of live births from first pregnancy after BC treatment | |
| 0 | 9 (7.8) |
| 1 | 76 (66.1) |
| 2 | 18 (15.7) |
| 3 | 1 (0.9) |
| Unknown | 11 (9.6) |
| Oncologic outcomes | |
| NED | 98 (85.2) |
| Local recurrence | 9 (7.8) |
| Regional recurrence | 5 (4.3) |
| Distant metastasis | 2 (1.7) |
| Secondary malignancy | 1 (0.9) |
| Dead | 0 (0.0) |
| Endocrine therapy (ETx) | N=64 |
| Discontinuation of ETx for pregnancy | 53 (46.1) |
| Finished planned regimen | 10 (8.7) |
| Stop for other reasons | 1 (0.9) |
| Duration of ETx before stop for pregnancy | N=53 |
| <1 Y | 5 (9.4) |
| 1–2 Y | 17 (32.1) |
| 2–3 Y | 20 (37.7) |
| 3–4 Y | 8 (15.1) |
| 4–5 Y | 3 (5.7) |
| ≥5Y | 0 (0.0) |